Case File
efta-efta01899002DOJ Data Set 10CorrespondenceEFTA Document EFTA01899002
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-efta01899002
Pages
0
Persons
0
Integrity
Loading PDF viewer...
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
To:
McCaffrey, Carlynl
l
From:
Jeffrey Epstein
Sent
Wed 4/3/2013 2:53:13 AM
Subject: Re: Re:
understood , but in an audit situation would that open up the 97 trust and its amendments as
opposed to waiting until after the final payment in aug?
On Tue, Apr 2, 2013 at 10:51 PM, McCaffrey, Carlyn <IMINS> wrote:
If we decant the 97 trust into a new trust before the Judah Trust ends, the Independent Trustees can
amend the Judah Trust so that its profits are distributed to the same trust that has received the
assets of the 97 Trust.
Carlyn S. McCaffrey I Partner w York, NY 10173
From: Jeffrey Epstein [mailto:ieevacation(agmail.com]
Sent: Tuesday, April 02, 2013 6:52 AM
To: McCaffrey, Carlyn
Subject: Re:
thanks as always .. also as the judah trust currently pours into the 97 trust ? , would you find it
more reasonbale to restate or decant after that event or can we make many amendments
before aug. I thought tha might open up the old later on?
On Tuc, Apr 2, 2013 at 6:49 AM, McCaffrey, Carlyle wrote:
No • What you're describing is a purchase of the BFP interests for a note secured by the art. That's not
a sale of the art.
Carlyn S. McCaffrey I Partner
McDermott Will & Emery LLP 1340 Madison Avenue, New York, NY 10173
From: Jeffrey Epstein [mailto:ieevacationeamail.com]
PROT3
PROT0
Sent: Monday, April 01, 2013 11:00 PM
To: McCaffrey, Carlyn
Subject:
would you see anything wrong with icon substituing a collateral note for the stock held by the
trust. if the art was collateral for expample?
The information contained in this communication is confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this communication in error, please notify us immediately by
return e-mail or by e-mail to ice), acaticm(iigipaij.cpm, and destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
IRS Circular 230 Disclosure: To comply with requirements imposed by the IRS, we
inform you that any U.S. federal tax advice contained herein (including any
attachments), unless specifically stated otherwise, is not intended or written to be
used, and cannot be used, for the purposes of (i) avoiding penalties under the
Internal Revenue Code or (ii) promoting, marketing or recommending to another
party any transaction or matter herein.
This message is a PRIVILEGED AND CONFIDENTIAL communication. This message
and all attachments are a private communication sent by a law firm and may be
confidential or protected by privilege. If you are not the intended recipient, you are
hereby notified that any disclosure, copying, distribution or use of the information
contained in or attached to this message is strictly prohibited. Please notify the
sender of the delivery error by replying to this message, and then delete it from your
system. Thank you.
Please visit http://www.mwe.com/ for more information about our Firm.
PROT4
PROT1
The information contained in this communication is confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this communication or any pan thereof is strictly prohibited
and may be unlawful. If you have received this communication in error, please notify us immediately by
return e-mail or by e-mail to jeevacation@gmail,com, and destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
The information contained in this communication is confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this communication in error, please notify us immediately by
return c-mail or by c-mail to jecvacation@gmail.com, and destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
PROT5
PROT2
Technical Artifacts (4)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Domain
agmail.comDomain
ieevacationeamail.comEmail
jecvacation@gmail.comURL
http://www.mwe.comRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.